How much revenue does palivizumab generate, and which companies sell it?
Palivizumab (brand Synagis) is a preventive monoclonal antibody used to reduce the risk of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in certain high-risk infants. The question of “palivizumab revenue” usually breaks down into (1) global market size for RSV prophylaxis and (2) product-level sales for Synagis by the manufacturer.
The provided information does not include any specific revenue figures for palivizumab/Synagis (global or by region), nor the selling company or annual sales.
What drives palivizumab revenue (treatable population, guidelines, pricing)?
Palivizumab revenue tends to be affected by:
- Eligibility criteria and RSV prophylaxis guidelines (which define which infants are considered “high risk”).
- Hospital/clinic purchasing patterns and seasonal demand cycles.
- Pricing and reimbursement coverage in each country.
- Competition from other RSV prevention products.
No additional inputs were provided here that quantify how these factors translate into revenue.
Does palivizumab face revenue pressure from newer RSV products?
Because the question is specifically about palivizumab revenue, users often want to know whether sales are declining due to newer alternatives (for example, newer prophylaxis options or longer-acting antibodies). The provided information does not list competitors, uptake trends, or any revenue impact.
Where can you find the palivizumab revenue numbers (10-K/annual reports, analyst tables)?
The most common places to find revenue figures are:
- The drug manufacturer’s annual report/10-K (product sales by geography/product line).
- Market research databases that estimate RSV prophylaxis market size and share.
- Public earnings call transcripts that sometimes break out major product sales.
No sources or figures were provided in the prompt to point to specific reported palivizumab revenue.
Can you estimate palivizumab revenue from dosing and patient counts?
In principle, palivizumab revenue can be approximated from:
- Eligible patient volume,
- Doses per season,
- Net price after discounts/rebates.
However, the prompt provides no numbers for patient counts, dosing schedules, or net pricing.
What I need to give you an exact revenue answer
To report palivizumab (Synagis) revenue accurately, I need at least one of the following:
- The year (e.g., 2023, 2024) and the geography (global vs. U.S. vs. specific countries).
- The company you mean (manufacturer) if you want product-level sales.
- A link/source table you want me to use, or permission to use external sources (not included in your prompt).
If you tell me the year and whether you want global or U.S. revenue, I can structure the answer around the specific figures you’re targeting.